Diabetic Neuropathies
Conditions
Brief summary
The study consists of two periods, the Screening Period (\ 3 weeks) and Treatment Period (12 weeks). Eligibility for the study will be determined by Screening tests, physical examination/medical history, and fulfilment of eligibility criteria including assessment of pain completed during the Screening Period. Potential participants will be required to provide written informed consent prior to any study-specific Screening procedures being performed. Following Screening assessments, patients will be randomized to receive either EMA401 300 mg BID or placebo. Patient study visits during the Treatment Period are at the end of baseline/randomization visit, and end of Weeks 3, 6, 9, and 12, for assessments.
Interventions
DRUGEMA401 600mg
DRUGPlacebo
Sponsors
Syneos Health
Spinifex Pharmaceuticals Pty Ltd
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients with Type I or Type II diabetes mellitus with painful, distal, symmetrical, sensory-motor neuropathy attributed to diabetes, of at least six months duration. * Be assessed as suffering from moderate to severe pain across the Screening Period. The assessment of moderate and severe pain will be made using an algorithm proprietary to Spinifex. The investigator/site staff will be informed immediately as to whether the patient is eligible or ineligible on the ePRO website based on the patient entering all relevant pain scores in the eDiary device. * Women of child bearing potential (WOCBP), must have a negative urine pregnancy test at the Screening visit (Visit 1) and within 72 hours prior to administration of IP.
Exclusion criteria
* Patients taking any topical treatment for their PDN at the time of Screening Visit 2 will be excluded, including lidocaine plaster, capsaicin patch, and any other topical preparations of these or any other topical medications (e.g., aspirin, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) for their PDN. * Have a blood pressure reading, after resting for at least five minutes, outside a systolic blood pressure range of 84 - 151 mmHg or a diastolic blood pressure \> 95 mmHg. If the blood pressure is outside of the range, a repeat measurement can be taken after the patient has rested. The repeat measurement should be used as the screening value. * Have serum aspartate transaminase (AST), or alanine transaminase (ALT) levels \> 1.5 x the upper limit of normal or have total bilirubin concentrations \> 1.5 x the upper limit of normal at Screening (Visit 1). * Have hemoglobin A1c \> 11 %. * Known history of, or positive laboratory results for hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection as defined by being seropositive for hepatitis B surface antigen (HBsAg), HCV antibodies or HIV antibodies respectively. * Have undergone neurolytic or neurosurgical therapy or use a neurostimulating device for PDN.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The efficacy of EMA401 compared to placebo in patients with painful diabetic neuropathy (PDN), as assessed by the difference in the weekly mean of the 24 hour average pain score, using an 11-point Numeric Rating Scale (NRS). | Change from Baseline to Week 12 |
Secondary
| Measure | Time frame |
|---|---|
| The effect of EMA401 compared to placebo on the weekly mean of the 24 hour worst NRS pain score. | Change from Baseline to Week 12 |
| The effect of EMA401 compared to placebo, on the Patient Global Impression of Change (PGIC). | Change from Baseline to Week 12 |
| The effect of EMA401 compared to placebo on the Brief Pain Inventory-Short Form (BPI-SF) average pain score. | Change from Baseline to Week 12 |
| The effect of EMA401 compared to placebo on the BPI-SF interference total score. | Change from Baseline to Week 12 |
| The effect of EMA401 compared to placebo on the Neuropathic Pain Symptom Inventory (NPSI). | Change from Baseline to Week 12 |
| The effect of EMA401 compared to placebo on the Insomnia Severity Index (ISI). | Change from Baseline to Week 12 |
| The safety and tolerability of EMA401 in patients with PDN as measured by number and severity of adverse events. | Change from Baseline to Week 12 |
| The proportion of EMA401 patients achieving a ≥ 30% and a ≥ 50% reduction in weekly mean 24 hour average pain score compared to placebo (i.e., responder rates). | Change from Baseline to Week 12 |
Outcome results
None listed